SynthesisJournal of managed care & specialty pharmacy2025
Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis.
Synthesis in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis.Targeted oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) in treating hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC) have been shown to be effective in prolonging progression-free survival with manageable safety profiles. However, the impact of CDK4/6is on health-related quality of life (HRQoL) is unclear.
objectiveTo comprehensively assess the association of CDK4/6is with HRQoL outcomes in patients with MBC.
methodsWe searched PubMed, Embase, and ClinicalTrials.gov to identify relevant randomized controlled trials (RCTs) of CDK4/6is on HRQoL outcomes in MBC. The CDK4/6is included in this study were palbociclib, ribociclib, and abemaciclib. Heterogeneity among studies was evaluated via the
resultsOf the 18 included RCTs, HRQoL outcomes were most widely measured with the general European Organization for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC QLQ-C30) (72%) and the EuroQol-5 Dimension (EQ-5D) (39%). There were no statistically significant differences between CDK4/6is and non-CDK4/6is in the EORTC QLQ-C30 global health status and EQ-5D index scores. Although CDK4/6is were associated with statistically significant worse outcomes in appetite loss, diarrhea, systemic side effects, and upset by hair loss, only the mean difference values for EORTC QLQ-C30 diarrhea of 8.56 (95% CI = 1.05-16.06;
conclusionsTreatment with CDK4/6is was not generally associated with worsening HRQoL among patients with MBC, except for the symptom-related, patient-reported measures of diarrhea and upset by hair loss. Understanding HRQoL impacts can help support health care decisions and treatment using CDK4/6is for patients with MBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.